Our therapies are based upon our unique understanding of T cells and the central role they play in immunity

T cells are at the heart of most immune responses. We have focused our research efforts on two classes of T cells: T effector cells and T regulatory cells.

T effector cells direct the immune response that destroys cancer cells, cells infected by viruses and bacteria, and—in the case of autoimmune disorders—our own tissues

T regulatory cells modulate the appropriate activation and inhibition of T effector cells, prevent the immune system from attacking normal cells and tissues, and—in cancer—inappropriately protect malignant cells

Inappropriate activation or inhibition of T cells plays a central role in type 1 diabetes mellitus (T1DM) and other autoimmune diseases and cancer.

• T1DM and other autoimmune diseases occur when inappropriately activated T effector cells attack normal cells and tissues, including:

• In cancer, T regulatory cells may prevent the development of a robust immune response that can attack and destroy cancer cells
  

Tolerx is a world leader in understanding the relationship between T effector and T regulatory cells and in developing immunotherapeutics that can safely and effectively manipulate that relationship in order to achieve a desired therapeutic effect.

• In cancer, Tolerx immunotherapeutics are designed to:

Additionally, we are developing surrogate markers and prognostic indicators of T regulatory cell function, which may possibly serve as early indicators in clinical studies.